Novel therapies and innovation for systemic sclerosis skin ulceration

Elsevier

Available online 5 January 2023, 101813

Best Practice & Research Clinical RheumatologyAuthor links open overlay panelAbstract

Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.

Keywords

Systemic sclerosis

Skin ulcer

Vasculopathy

Capillaroscopy

View full text

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif